LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other hematological malignancies. However, its impact on the immune system has not been defined. We here evaluated the effects of LBH589 on human myeloid dendritic cells (DCs) at clinically relevant concentrations. Exposure to LBH589 affected the surface molecule expression on immature and mature DCs, which was associated with DC maturation (CD83k), antigen presentation (human leukocyte antigen-ABCk) and T-cell co-stimulation (CD40k and CD86m). LBH589 decreased both protein and polysaccharide antigen uptake capacities by DCs. Importantly, LBH589 impaired DC function to stimulate antigen-specific immune responses, resulting in the significant reduction of invariant natural killer T-cell (CD1d-restricted) and T-cell (major histocompatibility complex-restricted) activation in innate and adaptive immunity. LBH589 also significantly repressed the production of interleukin (IL)-6, IL-10, IL-12p70, IL-23 and tumor necrosis factor-a by Toll-like receptor (TLR)3 and TLR4-induced DC activation, indicating an important role of HDAC activity in immune regulation and inflammation. RelB, a component of the nuclear factor-j B signaling pathway, was the key component regulated by HDAC inhibition in DCs. Together, our preclinical study demonstrates that LBH589 significantly impairs the phenotype and function of DCs, indicating a need for monitoring the immune status in patients receiving HDAC inhibitor therapy. It also provides a rationale to evaluate LBH589 activity for the treatment of inflammation.
Introduction
Gene expression, cellular differentiation and survival are regulated by the opposing activities of histone acetyltransferases and histone deacetylases (HDACs). Histone acetylation by histone acetyltransferases is associated with activation of transcription through relaxed chromatin structure, whereas deacetylation by HDACs induces a more condensed or inactive chromatin state, leading to gene repression. Although histones are the most thoroughly studied acetylated protein substrates, HDACs are also responsible for modifying the activity of diverse types of nonhistone proteins, including transcription factors and signal transduction mediators (for example, p53, c-Myb, hsp90, nuclear factor-kappa B (NF-kB), E2F1, sp3 and so on). [1] [2] [3] It is well recognized that HDAC activity is increased in cancer cells, resulting in altered gene transcription, impaired differentiation, increased cell survival and dysregulated proliferation. 1, 4 In the recent years, a group of structurally diverse HDAC inhibitors, such as sodium butyrate (small-molecular-weight carboxylates), suberoylanilide hydroxamic acid and Trichostatin A (hydroxamic acid), MS-275 (benzamides), Trapoxin (epoxyketones) and Apicidin (cyclic peptides), have been introduced for cancer treatment. 1 In addition to the antitumor activities observed, HDAC inhibitors have been reported to possess antiinflammatory and immunomodulatory properties both in vitro and in vivo. [5] [6] [7] [8] [9] LBH589 is a novel pan-HDAC inhibitor belonging to the class of cinnamic hydroxamic acids, which displays broad enzymeinhibitory activity in the low nano-molar range. 3 Preclinical studies have shown that LBH589 has potent antitumor activity. It induces hyperacetylation of core histone proteins, resulting in modulation of protein expression, leading to cell cycle arrest in the G2/M phase and apoptosis. In addition, LBH589 appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1 alpha and vascular endothelial growth factor, thus impairing endothelial cell chemotaxis and invasion. [10] [11] [12] [13] LBH589-induced growth inhibition and cytotoxicity has been observed in cutaneous T-cell lymphoma, chronic myelogenous leukemia, acute myeloid leukemia, Hodgkin's lymphoma, breast, prostate, colon and pancreatic cancer cell lines. 3, 14 Currently, LBH589 is undergoing phase I/II clinical trials in multiple myeloma, and a series of solid and hematological malignancies.
Although the role of HDAC inhibition by LBH589 has been widely studied in the malignant cells, its effects on normal human immune function have not yet been defined. Dendritic cells (DCs) are potent antigen-presenting cells that have a key role in the initiation and regulation of antigen-specific immune responses through antigen uptake, processing and presentation. DCs also have a crucial role in the modulation of innate and adaptive immunity through the production of cytokines (for example, interleukin (IL)-10, IL-12 and IL-23). 15, 16 The effects of HDAC inhibition on DC-mediated antigen-specific immune responses have been evaluated for some of the HDAC inhibitors; 9,17 however, it has been restricted to the observation of the major histocompatibility complex (MHC)-mediated T-cell activation. In this study, we have systematically investigated the impact of LBH589 treatment on the function of DCs involved in both classic (MHC-restricted) and non-classic (CD1d-restricted) lymphocyte immune responses. We have also evaluated the effects of LBH589 treatment on the cytokine production by Toll-like receptor (TLR)3-and TLR4-induced DC activation. Our study demonstrates a significant impairment of the phenotype and function of DCs on LBH589 treatment.
Materials and methods

Reagent
HDAC inhibitor LBH589 was provided by Novartis Pharmaceutical Inc. (Cambridge, MA, USA). It was dissolved in dimethyl sulfoxide at 1 mM and kept at À70 1C. The drug was diluted in culture medium and used at various concentrations as indicated.
Generation of DCs
Healthy donor leucopacks were obtained from the Dana-Farber Cancer Institute following informed consent approved by the institutional review boards. To generate monocyte-derived immature DCs, CD14 þ cells were isolated from peripheral blood mononuclear cells by magnetic microbeads (Miltenyi Biotec, Auburn, CA, USA) and cultured for 6 days in 10% of heat-inactivated fetal bovine serum RPMI1640 medium supplemented with the granulocyte-macrophage colony stimulating factor (GM-CSF) (1000 U/ml) and IL-4 (10 ng/ml; both from R&D system, Minneapolis, MN, USA) every 3 days. Mature DCs were induced by lipopolysaccharide (LPS) (100 ng/ml) or polyinosinic:polycytidylic acid (poly(I:C)) (25 mg/ml; both from Sigma-Aldrich, St Louis, MO, USA) following 6 days of culture. Peripheral blood untouched CD1c (BDCA-1) þ and CD141 (BDCA-3) þ myeloid DCs were directly isolated from peripheral blood mononuclear cells using the human myeloid dendritic cell isolation kit (Miltenyi Biotec) and immediately used for the functional assay.
Isolation of T cells and establishment of invariant natural killer T (iNKT) cell lines
T cells were obtained from peripheral blood mononuclear cells by negative selection using the Pan T cell isolation kit II (Miltenyi Biotec). The establishment of iNKT cell lines was described previously. 18 In brief, TCRVa24 þ cells were enriched from healthy donor peripheral blood mononuclear cells and stimulated with a-galactosylceramide (a-GalCer) (100 ng/ml; Kirin Brewery Co. Ltd., Gunma, Japan)-pulsed mature DCs in the presence of IL-2 (50 U/ml; Chiron Corporation, CA, USA). TCRVb11 þ cells were further enriched from the proliferating cells and restimulated with a-GalCer-pulsed mature DCs every week. The frequencies of expanded iNKT cells were monitored by quantifying Va24 þ Vb11 þ cells using flow cytometric analysis.
Antigen uptake assay
The antigen uptake ability by immature DCs was evaluated using Alexa Fluor 488-conjugated 45-kDa protein A (200 mg/ml), 20-kDa protein G (200 mg/ml) and fluorescein isothiocyanate (FITC)-conjugated 40-kDa dextran (1 mg/ml; all from Invitrogen, Baltimore, MD, USA). In brief, following 24 h treatment at various concentrations, control or LBH589-treated immature DCs were stained with individual antigen, incubated at 37 1C for 45 min, washed with RPMI1640, and analyzed by flow cytometry.
DC-mediated T-cell immune responses
(1) To determine the effects of LBH589 on immature DCs or directly isolated blood myeloid DCs, cells were pre-treated with or without LBH589 for 24 h, subsequently collected, extensively washed three times and then pulsed with tetanus toxoid (0.5 mg/ml; Calbiochem, Gibbstown, NJ, USA) overnight in the presence of LPS (100 ng/ml). DCs were next harvested, washed and seeded into 96-well plates to stimulate autologous T cells.
(2) To determine the effects of LBH589 on DCs during maturation, DCs following 6 days of culture were treated with or without LBH589 for 24 h, and simultaneously pulsed with tetanus toxoid (0.5 mg/ml) in the presence of LPS. Cells were subsequently harvested, extensively washed three times and added into 96-well plates to culture with autologous T cells. (3) The effect of LBH589 on directly isolated myeloid DCs was also tested by allogeneic immune responses. Cells were pretreated with LBH589 for 24 h, extensively washed and loaded into 96well plates to culture with allogeneic T cells. LBH589 was used at 10 nM for all the experiments. 1 Â 10 5 T cells were added into each well and cultured with the above control or LBH589treated DCs in the ratio of 10:1 T cells to DCs, in the presence of 40 U/ml of IL-2. In all cases, supernatants were collected at 48 h of culture and subjected to the measurement of interferon (IFN)-g production by enzyme-linked immunosorbent assay (ELISA).
DC-mediated iNKT cell immune responses
DCs following 6 days of culture were treated with or without LBH589 at 10 nM for 24 h. During the same time, DCs were pulsed with a-GalCer (100 ng/ml) in the presence of LPS (100 ng/ml). Cells were subsequently harvested, extensively washed three times and seeded into 96-well plates. 1 Â 10 5 iNKT cells were added into each well and cultured with the above control-or LBH589-treated DCs for 48 h in the ratio of 5:1, in the presence of 40 U/ml of IL-2. Supernatants were collected and subjected to the detection of IFN-g, IL-2 and IL-4 production by ELISA.
Cytokine production by TLR3-and TLR4-induced DC activation
DCs following 6 days of culture were placed into a 24-well plate at 1 Â 10 5 cells/ml and matured by poly(I:C) (25 mg/ml) or LPS (100 ng/ml) in the absence or presence of LBH589 at various concentrations. After 24 h culture, the supernatants were collected for the measurement of IL-6, IL-10, IL-12p70, IL-23 and tumor necrosis factor (TNF)-a production by ELISA.
Western blot
DCs following 6 days of culture were seeded into six-well plates at 1.5 Â 10 6 cells per well in 3 ml DC culture medium, treated with or without LBH589 at various doses (2.5, 10 and 20 nM) for 18 h, or at 10 nM with various time points (12, 18 and 24 h), in the presence or absence of LPS (100 ng/ml) or poly(I:C) (25 mg/ml), respectively. Cells were lysed by using radioimmunoprecipitation assay (RIPA)-lysis buffer (Boston BioProducts, Boston, MA, USA) in combination with complete protease inhibitor cocktail (Roche, Indianapolis, IN, USA), 2 mM sodium orthovanadate, 5 mM sodium fluoride, 5 mg/ml aprotinin, 5 mg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride (all from Sigma-Aldrich, St Louis, MO, USA). Proteins were separated by 10% of bis-tris gel electrophoresis, transferred onto polyvinilydene difluoride membranes (Bio-Rad, Hercules, CA, USA), and immunoblotted with anti-NF-kB p65 and RelB (both from Cell Signaling Technology, Beverly, MA, USA) and anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies.
Cytokine assays
Released cytokine levels were determined by ELISA. IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-23, IFN-g and TNF-a were quantified by the Quantikine immunoassay (R&D Systems) according to the manufacturer's instruction.
Cell viability assay and phenotypic characterization
Cell viability of the DCs with or without LBH589 treatment and of T cells/iNKT cells in response to control or LBH589pretreated DCs was evaluated by staining with Annexin V and propidium iodide (BD Pharmingen, San Diego, CA, USA) and quantifying by flow cytometry. The following antibodies were used for the DC phenotypic analysis: phycoerythrin (PE)-conjugated anti-CD40, anti-CD80, anti-CD83, anti-CD86, anti-human leukocyte antigen (HLA)-ABC, and anti-HLA-DR monoclonal antibodies (BD Pharmingen). FITC-conjugated anti-TCRVa24 and PE-conjugated anti-TCRVb11 monoclonal antibodies (Immunotech, Marseille, France) were used to monitor the frequencies of iNKT cells. Flow cytometry was performed with a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA).
Statistical analysis
Statistics analyses were done by Student's t-test. Po0.05 was considered significant.
Results
Effects of HDAC inhibition by LBH589 on DC survival
We first evaluated the effect of HDAC inhibition on survival of both immature and mature DCs. Monocyte-derived DCs were cultured with GM-CSF and IL-4 for 6 days, and maturation was induced by LPS. Cells were exposed to clinically relevant concentrations of LBH589 (2.5-20 nM) for 24 h, and viability was checked by annexin V and propidium iodide staining. As seen in Figure 1 , although 24-h treatment with LBH589 at 10 nM did not affect the viability of immature DCs (490%), a higher concentration (20 nM) induced it. For all subsequent studies with immature DCs, we used up to 10 nM concentration of LBH589 treatment. On the other hand, no significant apoptosis was induced by LBH589 up to 20 nM concentration in mature DCs. Similar effects were observed on DCs matured with IL-1b and TNF-a (data not shown).
HDAC inhibition by LBH589 modulates phenotypes of immature and mature DCs
We next investigated the effects of HDAC inhibition on the expression of a series of surface molecules that are critical for DC function. Immature and mature DCs were cultured with or without LBH589 for 24 h at various concentrations. Compared with the control, LBH589 treatment at 10 nM led to a significant downregulation of CD40, CD83 and HLA-ABC expression on immature DCs. In contrast, we also observed the upregulation of CD86 expressions on LBH589 treatment (Figure 2a ). Similar to those observed on the immature DCs, LBH589 treatment (10 and 20 nM) resulted in the decreased expression of CD40, CD83 and HLA-ABC on mature DCs, compared with control. No obvious alteration was shown in the expression of CD86 (Figure 2b ). CD80 and HLA-DR expressions were not significantly affected by LBH589 in both immature and mature DCs.
HDAC inhibition by LBH589 decreases antigen uptake by immature DCs
We next tested whether HDAC inhibition affected the antigen uptake capacity by immature DCs, using various sizes and forms of antigens. We observed that LBH589 treatment (2.5 and 10 nM) significantly reduced the uptake of both protein antigens (45-kDa protein A and 20-kDa protein G) by DCs, compared with control. Our data also demonstrate that HDAC inhibition repressed the ability of polysaccharide antigen uptake, evidenced by significant inhibition of Dextran (40-kDa) uptake by DCs on LBH589 treatment (10 nM) ( Figure 3 ). 
HDAC inhibition by LBH589 impairs DC-mediated T-cell activation
To investigate whether HDAC inhibition affected DCs' capacity to activate antigen-specific T-cell response, the IFN-g production by T cells in response to control or LBH589 (10 nM)-treated DCs was measured by ELISA. As seen in Figure 4a , on stimulation with tetanus toxoid-pulsing DCs that were pretreated with LBH589 at immature stage, the IFN-g production was significantly reduced at 48 h of culture, indicating a repressed DC function to T-cell activation. Exposure of DCs to LBH589 during LPS-induced maturation resulted in a similar effect, as seen in Figure 4b . Importantly, we confirmed that LBH589 pretreatment of freshly isolated blood myeloid DCs led to significant inhibition of antigen-specific ( Figure 4c) and allogenic (Figure 4d ) T-cell immune responses. To demonstrate that the impaired IFN-g production by T cells was not due to the effect of residual LBH589, we performed the T-cell apoptosis assay after 48 h of incubation in the above conditions. No significant difference in T-cell viability was observed between cultures with control-and LBH589-treated DCs following washout (Supplementary Information).
HDAC inhibition by LBH589 impairs DC-mediated iNKT cell activation
In addition to presenting peptide antigens, DCs also present glycolipids to activate iNKT cells. We therefore addressed whether HADC inhibition affected DCs' function to activate CD1d-restricted iNKT cells, by measuring the cytokine production by iNKT cells on stimulation with a-GalCer-pulsing control or LBH589 (10 nM)-treated DCs. The frequency of Va24 þ Vb11 þ cells from established primary iNKT cell lines was 98%, as confirmed by flow-cytometric analysis (Figure 5a ). As seen in Figure 5b , compared with control, significant reduction of both Th1-type cytokines (IFN-g and IL-2) and Th2-type cytokines (IL-4) produced by iNKT cells was observed in the culture of LBH589treated DCs, demonstrating an impaired DC function to iNKT cell activation. No significant difference in iNKT cell viability was observed between stimulation with control or LBH589treated DCs (Supplementary Information). 
HDAC inhibition by LBH589 represses cytokine production by DCs
DCs have a crucial role in the innate and adaptive immune responses through cytokine regulation. Thus, we evaluated whether HDAC inhibition could modulate the cytokine production by DCs. DCs were treated with or without LBH589 (2.5, 10 and 20 nM) for 24 h during LPS-or poly(I:C)-induced maturation and the cytokine production was measured by ELISA. As seen in Figure 6 , compared with controls, LBH589 treatment significantly inhibited a series of cytokine production by DCs, including IL-6, IL-10, IL-12p70, IL-23 and TNF-a. The significant reduction appeared at the lowest LBH589 concentration (2.5 nM), suggesting an essential role for HDAC activity in the cytokine production by DCs.
HDAC inhibition by LBH589 impairs the NF-kB signaling pathway in DCs
We next evaluated the mechanism responsible for LBH589induced cytokine reduction by DCs. We observed that HDAC inhibition by LBH589 significantly reduced the expression of RelB, an NF-kB signaling component, in a dose-dependent manner (2.5, 10 and 20 nM) following 18 h of treatment in both immature DCs and DCs during LPS or poly(I:C)-induced HDAC inhibitor LBH589 modulates the phenotype and functions of myeloid DCs W Song et al maturation. We also observed the reduction of RelB expression from 12 to 24 h of LBH589 treatment at 10 nM. We did not observe a significant alteration in the expression of p65, another NF-kB component, in the above conditions (Figure 7) .
Discussion
In the present study, we report that HDAC inhibition by LBH589 significantly modulates the phenotype and function of myeloid DCs. HDAC inhibition led to both up-and downregulation of important surface molecules on DCs, which were responsible for antigen-specific immune responses. CD40, CD80 and CD86 are the co-stimulatory molecules mediating T-cell activation. On LBH589 treatment, CD40 expression was significantly reduced at both immature and mature states, although the CD86 expression was upregulated on immature DCs. These discrepant results are consistent with the other report evaluating the effects of LAQ824, another HDAC inhibitor, on DCs, 17 whereas suberoylanilide hydroxamic acid induced downregulation of both CD40 and CD86 expression on DCs. 9 We also monitored the alteration of antigen-presenting molecules. The expression of HLA-ABC was significantly inhibited. In combination with the reduction of CD83 on both immature and mature DCs, our results suggest that HDAC activity may have an important role in DC maturation as well as in generation of T-cell responses. Importantly, in the present study, we demonstrate that HDAC activity has a crucial role in DC-mediated antigen-specific immune responses, through both classic (MHC-mediated) and non-classic (CD1d-mediated) antigen-presenting pathways. In an MHC-restricted manner, DCs present peptides to activate T cells, the key mediators in the adaptive immunity. Our study has shown that LBH589 treatment of immature DCs or during LPS-induced maturation repressed their ability to activate T cells. LBH589 pretreatment of directly isolated myeloid DCs also showed a similar effect. The published reports of a similar effect of other HDAC inhibitors (suberoylanilide hydroxamic acid, MS-275) on DC-mediated T-cell immune responses suggest that these actions are related to the effect of the drugs on the type of target (HDAC) rather than separate direct drug effects. Distinct from conventional T cells, iNKT cells constitute an innate lymphocyte lineage that has an important role in regulating immune responses. iNKT cells recognize glycolipid ligands presented by CD1d and are characterized by their capacity to rapidly produce large amounts of immunoregulatory cytokines to activate downstream immune effectors. [19] [20] [21] We here report that LBH589 also repressed DC-mediated antigenspecific iNKT cell immune responses. To our knowledge, this is the first report to reveal the role of HDAC activity in CD1dmediated antigen presentation.
Together, our study revealed that HDAC inhibition on DCs significantly affected both innate and adaptive immune responses, mediated by the major components of iNKT cells and T cells, respectively. These may be caused by reduced expression of surface molecules associated with T/iNKT cell activation and inhibited by antigen uptake ability, which were demonstrated in this study, or, owing to repressed antigen processing and/or presentation capacities on HDAC inhibition. Further evaluation of the molecular mechanisms of action of LBH589 on MHC class I, MHC class II and CD1d pathways will benefit our understanding of HDAC activity in DC-mediated antigen presentation. Moreover, owing to the crucial role of HDAC activity in DC function, care should be taken to avoid the use of HDAC inhibitors in antigen-specific vaccination strategies.
When exposed to pathogens, particularly the ligands for TLRs, DCs produce an array of pro-inflammatory cytokines, which create an environment in which the T cells undergoes expansion and differentiation. 22 Cytokines specifically involved in the induction of a given T helper cell subset have been demonstrated: IL-12 for Th1 and IL-23 for Th17 cells. 16, 22, 23 We compared these cytokine productions by LPS-or poly(I:C)activated DCs with or without LBH589 treatment. A significant reduction was seen for both IL-12 and IL-23 production at 2.5 nM drug concentration. In addition, we showed significant repression of IL-6, IL-10 and TNF-a production by LBH589treated DCs. Together, our data demonstrate that HDAC activity has a crucial role in the immune system by modulating DC-produced cytokines, which are important components in Figure 7 HDAC inhibition by LBH589 impairs the NF-kB signaling pathway in DCs. DCs following 6 days of culture were seeded into six-well plates with or without LBH589 at the indicated doses (2.5, 10 and 20 nM) for 18 h (a), or at 10 nM with the indicated time points (12, 18 and 24 h) (b), in the presence or absence of LPS (100 ng/ml) or poly(I:C) (25 mg/ml). Cells were then harvested and lysed, proteins separated by 10% of bis-tris gel electrophoresis, and immunoblotted with anti-RelB, anti-NF-kB p65 and anti-actin antibodies. LBH589 treatment significantly reduces the expression of RelB in DCs.
regulating T-cell polarization, NK cell activation, as well as inflammation.
To address the mechanism mediating the LBH589-induced reduction in cytokine production by DCs, we evaluated the alteration in proteins of mitogen-activated protein kinase, NF-kB and IRF-5 signaling pathways, which participate in TLR3 or TLR4 activation to produce pro-inflammatory cytokines. [24] [25] [26] Our study revealed that RelB of the NF-kB signaling pathway is the key component regulated by HDAC. No obvious alteration in mitogen-activated protein kinase (p38, JNK) and IRF5 signaling pathways was observed either by protein expression or by phosphorylation studies (data not shown). We have also evaluated the effect of LBH589 on the expression of indoleamine 2,3-dioxygenase (IDO), a repressor of DC activation. However, our data showed that LBH589 significantly downregulated IDO expression after 12-24 h of treatment in both LPS-and poly(I:C)-induced DC activation (no IDO expression was seen in the immature DCs), which is opposite to our understanding of the repressive function of IDO in DCs (data not shown). Further studies to elucidate this finding may bring us a new insight into understanding the HDAC activity in DCs.
In summary, our study demonstrates that HDAC inhibition by LBH589 significantly impairs the biology of myeloid DCs. Our pre-clinical data indicate a need to monitor immune functions in patients receiving HDAC inhibitor therapy. In contrast, the significantly reduced pro-inflammatory cytokine production may suggest a need to investigate the use of this agent in treatment of inflammatory diseases as well as autoimmune disorders.
